UPDATE 1-Fresenius says Akorn troubles could continue into next year
November 02, 2017 at 03:54 AM EDT
FRANKFURT, Nov 2 (Reuters) - German healthcare group Fresenius SE said on Thursday that weakness at Akorn , the U.S. maker of liquid generic drugs it has agreed to buy, could continue into next year but the deal was still worth it over the longer term.
